My Steps
Toward Wellness

Take a positive step forward with a regular walking program. We’ll encourage you every step of the way.

2 opportunities to walk

My Steps for Healthy Living

This self-paced walking program* challenges you to increase your wellness by gradually increasing your daily steps. For those diagnosed with Alpha-1, there are many health benefits to walking.8

  • Strengthens muscles.
  • Improves circulation and enhances oxygen delivery.
  • Increases stamina and decreases fatigue.
  • Elevates mood and sense of well-being.


  • Enroll today! Call 1-866-936-2472 or complete the online enrollment.
  • Expect your FREE pedometer and welcome kit in the mail.


  • Take your pedometer on a “test walk.”
  • Set a “daily steps” goal. Your goal should be challenging but achievable.
  • Plan to increase your goal by 10% each month.


  • Walk every day!
  • Record your steps on the log sheet.
  • At the end of each month, submit your “report card.”
  • Receive a motivational reward (regardless if you met your goal or not).


  • Feel better—physically, mentally, and emotionally.
  • Be proud. You are taking steps in the right direction.
  • Keep going.

*Consult with your doctor to determine if a walking program is right for you.

Or call 1-866-ZEMAIRA (1-866-936-2472).

Download monthly log sheet.
Complete monthly report card.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2018 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006d(1) 5/2015